Ivermectin Mebendazole Cancer Study
Research on drug repositioning has invigorated cancer studies. Researchers have begun discovering new cancer solutions using already existing drugs. Ivermectin Mebendazole have recently started to attract attention. They have been used to treat parasitic infections for decades. Laboratory studies have proven that they can affect cancer cells in many ways.
Studies have begun investigating how these drugs can complement already existing cancer treatment options. Although initial findings have shown great potential, the medical community believes that further research is a requirement prior to consideration of these two drugs as standard cancer treatment options.
Key Takeaways
- Ivermectin Mebendazole are antiparasitic drugs and are not FDA approved to treat cancer.
- Laboratory studies have provided evidence that the two drugs can assist in the death of cancer cells and in the slowing of cancer.
- An observational study showed great potential for patients who used the drugs, however, the study was not a clinical randomized trial.
- Research is still a requirement to prove the drugs are both safe and effective.
- The use of standard cancer treatment must be discussed with an oncology team prior to its use.
Why Are Researchers Studying Ivermectin Mebendazole?
Researchers have information that shows both skills in disrupting numerous biological functions that pertain to how tumors grow.
Ivermectin may have the following effects, according to preclinical studies:
- Inhibit the proliferation of cancer cells
- Induce apoptosis
- Decrease the activity of cancer stem cells
- Influence the signaling pathways related to the development of tumors
Mebendazole has shown some encouraging in vitro results by:
- Inhibiting the proliferation of cancer cells
- Inhibiting the formation of blood vessels in tumors
- Inducing death of cancer cells
- Decreasing the growth of tumors in animal models
The results of the two studies are attracting considerable attention because both drugs are inexpensive, and their approved uses have well-established safety profiles.
Latest Ivermectin Mebendazole Cancer Study
One of the most mentioned studies was published in Anticancer Research, and the study can be found on PubMed.
Researchers followed cancer patients who participated in a physician-supervised protocol who compounded Ivermectin Mebendazole.
This observational study was initially participated in by 197 patients and of this, 122 patients completed the follow-up six months later.
Each patient received prescriptions of Capsules containing:
Patients were allowed by the physician to take up to 4 capsules per day.
As opposed to randomized clinical trials, this study was based on real outcomes and therefore was given a degree of caution in its interpretation. However, the outcomes provided information of a preliminary nature about possible future studies and did not assert a causal relationship between the intervention and the outcomes that were achieved.
The 6-Month Study Follow-up Outcomes
The following outcomes were achieved by the 122 patients that completed the follow-up:
Study Results Table
| Outcome | Percentage |
| Reported clinical benefit (tumor shrinkage, no evidence of disease, or stable disease) | 84.4% |
| Tumor shrinkage or no current evidence of disease | 48.4% |
| Stable disease | 36.1% |
| Disease progression | 15.6% |
Because this study was observational, without a randomized control group, results can only be seen as preliminary.
How Are Ivermectin Mebendazole Anticancer Drugs?
The mechanisms remain unknown. However, even now, researchers are considering several hypotheses for the anticancer effects of ivermectin mebendazole.
Ivermectin and mebendazole might:
- Interfere with the process of cancer cell proliferation
- Induce programmed cell death
- Decrease the inflammatory response inside the tumor
- Alter cellular communication and pathways of cancer
- Decrease the formation of blood vessels that supply the tumor
Ivermectin mebendazole are also being studied to determine whether cancer treatment will be enhanced by these medications combined with chemotherapy, immunotherapy, or radiation.
What Are the Limitations?
Although the recent observational study has garnered significant interest, important limitations need to be presented.
The study:
- was not randomized
- did not include a placebo control group
- did not rely on objective (measurable) outcomes
- did not describe the cause and effect relationship
- demanded verification in larger clinical trials.
Due to the limitations mentioned above, cancer specialists have advised taking a conservative approach with the results.
Should Cancer Patients Consider These Medications?
Before trying anything new, patients should consult with their oncologists to discuss available options.
The researching of ivermectin mebendazole continues, but they should not be used in place of evidence-based medicine that consists of surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapies outside of a clinical trial, or in the care of a certified medical practitioner.
Those who are drug repurposing research inclined may ask their healthcare providers about current clinical trials for these drugs.
Conclusion
The new cancer research study involving ivermectin mebendazole has become very popular because of the positive results that came from the cancer patients in an observational study. Among the cancer patients that had completed a follow-up study after six months, the most of them reported positive results of stabilization or improvement in their conditions. Only a small number of patients reported progression to a worse state of illness.
This outcome is very encouraging but should not be conclusively interpreted to mean that cancer patients can be treated with ivermectin mebendazole. A greater number of randomized control trials are necessary to determine if these treatment options offer a meaningful clinical benefit that is not already offered by the current standard of care.
Ivermectin and mebendazole remain viable candidates for research, but patients are encouraged to abide by the standard of care and monitor the results of research in this area of medicine.
Scientific Resources
- Hulscher N, et al. Real World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. Anticancer Research. Indexed on PubMed.
- PubMed – Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?
- Frontiers in Pharmacology – Critical Dysregulated Signaling Pathways: Repositioning of Mebendazole for Cancer Therapy.
- National Cancer Institute – Information on clinical trials and drug repurposing in oncology.